Answers are grounded in this paper and cite their sources.
Based on data from the whole INBUILD trial, nintedanib reduced the risk of events indicating ILD progression.
No takes yet. Share an insight, caveat, or question.
Flaherty et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: